Ingrezza (valbenazine) / Neurocrine Biosciences, Tanabe Pharma - LARVOL DELTA

Long-Term Safety and Efficacy of Once-Daily INGREZZA® (Valbenazine) in Huntington’s Disease Chorea: Results From the 5-Year KINECT®-HD2 Study (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders

Efficacy and Adverse Events of Tetrabenazine, Deutetrabenazine, and Valbenazine in Huntington’s Disease (MDS Congress 2026) - No abstract available

Adverse events • Clinical • CNS Disorders • Movement Disorders

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Neurocrine Biosciences | N=50 ➔ 100 | Trial completion date: Jan 2027 ➔ Jun 2028 | Trial primary completion date: Jan 2027 ➔ Jun 2028

Enrollment change • Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

Valbenazine Improves Quality of Life, Functionality, and Movement Severity in Patients With Tardive Dyskinesia: Findings From the KINECT-PRO™ Study. (PubMed, CNS Spectr) - No abstract available

HEOR • Journal • Movement Disorders

VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know. (PubMed, Focus (Am Psychiatr Publ)) - "This report reviews efficacy and safety considerations for the two FDA-approved VMAT2 inhibitors, deutetrabenazine and valbenazine, which are recommended as first-line treatment for troublesome TD in current practice guidelines. Overall, these VMAT2 inhibitors offer significant benefit to patients experiencing TD through improved health and quality of life."

Journal • Review • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mood Disorders • Movement Disorders • Psychiatry

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results (TradingView) - "INGREZZA second-quarter 2026 net product sales were $716 million, representing 15% growth year-over-year. Results reflected double-digit prescription volume growth in TRx and record NRx driven by strong patient demand; INGREZZA full year 2026 guidance was increased from a range of $2.7 billion to $2.8 billion up to $2.825 billion to $2.875 billion."

Sales • Huntington's Disease

Green spectrofluorimetric method using nitrogen-phosphorus carbon quantum dots and Box-Behnken optimized salting-out assisted extraction for valbenazine determination in environmental samples. (PubMed, Sci Rep) - "Comprehensive green analytical chemistry assessment using AGREE (0.64), CaFRI (82/100), BAGI (72.5/100), and WAC RGB 12 model (87.7% whiteness) indicated satisfactory environmental sustainability, low carbon footprint, and high practical applicability, with reduced organic solvent consumption and shorter analysis time relative to conventional LC-MS/MS and HPLC methods reported for structurally related pharmaceuticals. The method offers a green, cost-effective proof-of-concept analytical platform with demonstrated feasibility for potential future monitoring of emerging pharmaceutical contaminants in aquatic ecosystems."

Journal

Neurocrine Biosciences, Inc…announced new post-hoc data from the KINECT 4 clinical trial demonstrating that adults with tardive dyskinesia (TD) treated with INGREZZA (valbenazine) capsules experienced clinically meaningful and robust improvements in involuntary movement severity, including those who did not meet the stringent symptomatic remission threshold. (PRNewswire) - "A new post-hoc analysis further demonstrated that clinically meaningful improvements were observed even among patients who did not meet the more stringent symptomatic remission threshold. Among the 41% of patients (42/103) who did not meet the symptomatic remission threshold at Week 48, 86% (36/42) achieved ≥30% total AIMS score reduction (characterized by the authors as clinically meaningful), and 67% (28/42) achieved ≥50% reduction."

P3 data • Bipolar Disorder • CNS Disorders • Major Depressive Disorder • Schizophrenia

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada (clinicaltrials.gov) - P3 | N=7 | Enrolling by invitation | Sponsor: Neurocrine Biosciences | Trial completion date: Apr 2026 ➔ Apr 2028 | Trial primary completion date: Apr 2026 ➔ Apr 2028

Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease (clinicaltrials.gov) - P3 | N=154 | Completed | Sponsor: Neurocrine Biosciences | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Nov 2025 | Trial primary completion date: Mar 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders

Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Virginia Commonwealth University | Trial completion date: May 2026 ➔ Jun 2027 | Trial primary completion date: May 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • CNS Disorders • Dystonia • Movement Disorders

Improvement in functional areas with valbenazine in mild TD movement severity: real-world data from a chart extraction and clinician survey (APA 2026) - "Most patients with clinician-reported mild movement severity were impacted in at least 1 functional area. Nearly all valbenazine-treated patients in this subgroup that had functional impacts experienced improvement in functional status, independence, socioemotional, or physical areas of their lives. Results in this subgroup support the treatment guidelines and demonstrate that patients who have been classified as having mild TD can be impacted by their movements and see improvement with valbenazine treatment."

Clinical • Real-world • Real-world evidence • CNS Disorders • Mood Disorders • Movement Disorders • Schizophrenia

Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report. (PubMed, Neuropsychopharmacol Rep) - "ECT may provide clinically meaningful short-term improvement in severe refractory tardive dystonia even in the absence of active depressive symptoms; relapse after acute treatment may occur, and continuation strategies may be required."

Journal • Anesthesia • CNS Disorders • Depression • Dystonia • Epilepsy • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry

VALBENAZINE IMPROVES PHYSICAL, SOCIAL, AND EMOTIONAL IMPACTS ON THE TARDIVE DYSKINESIA IMPACT SCALE (TDIS): POST HOC ANALYSES OF KINECT-PRO™ DATA (ISPOR 2026) - "Items in the Emotional, Social, Mouth/Throat Function, and Pain scales were among the most impacted at baseline. However, substantial improvements were observed across all TDIS items at Week 24. These findings suggest utility of the TDIS for evaluating treatment-related changes in the physical, social, and emotional impacts of TD."

Retrospective data • Movement Disorders

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials. (PubMed, J Clin Psychiatry) - "TDIS showed moderate correlation with treatment response as measured by Patient's Global Impression of Change (r=0.30) and Clinician's Global Impression of Change (r=0.34) scores. TDIS is the only disease-specific PRO that has been validated in individuals with TD and complements ClinROs and other PROs by providing a comprehensive picture of TD impact beyond movement symptoms and can measure potential benefit of TD treatments."

Journal • Movement Disorders

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy (clinicaltrials.gov) - P3 | N=86 | Completed | Sponsor: Neurocrine Biosciences | Active, not recruiting ➔ Completed

Trial completion • Cerebral Palsy • CNS Disorders • Movement Disorders

A Case of Wilson’s Disease With Initial Unilateral Chorea and Contralateral MRI Changes (AAN 2026) - "The patient was restarted on her maintenance trientine regimen of 250 mg three times daily and zinc, with marked improvement of chorea. Trials of clonazepam, deutetrabenazine, and valbenazine produced no significant benefit...Conclusions This case represents one of the first reported instances of initial unilateral neurological manifestations of Wilson’s disease accompanied by contralateral MRI changes. It underscores the importance of recognizing atypical neurological presentations of Wilson’s disease."

Clinical • Diabetes • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Movement Disorders

Grinding Truths: Cocaine-associated Oromandibular Dystonia and the Hidden Role of Adulterants (AAN 2026) - "Trials of valbenazine and trihexyphenidyl worsened dystonic movements. While clonazepam provided relief, it was short lived...Clinicians should consider stimulant-induced and adulterant-related causes in new-onset movement disorders. Broader toxicology testing, increased clinical awareness, and the use of botulinum toxin for refractory cases may improve patient outcomes and diagnostic accuracy."

Clinical • Cardiovascular • CNS Disorders • Dystonia • Immunology • Mental Retardation • Movement Disorders

Real-world Persistence in Patients with Tardive Dyskinesia: A Comparative Study of Valbenazine and Deutetrabenazine XR (AAN 2026) - "Objective Evaluate persistence outcomes among matched deutetrabenazine-extended-release (XR) and valbenazine cohorts. Higher persistence rates with valbenazine were seen after the first month and were sustained through the 6-month follow-up. Future studies may investigate potential reasons for differences in persistence, such as titration difficulty, clinical effectiveness, and tolerability."

Clinical • Real-world • Real-world evidence • CNS Disorders • Huntington's Disease • Movement Disorders

Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (AAN 2026) - "91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD. Conclusions Most participants with TD who reported previously using valbenazine and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD."

Clinical • Genetic Disorders • Huntington's Disease • Movement Disorders

Patients with Tardive Dyskinesia (TD) Report Improved Quality of Life Scores and Met TD Remission Criteria with Once-daily Valbenazine in KINECT-PRO™, Regardless of TD Movement Severity at Baseline (AAN 2026) - P4 | "Safety and tolerability were consistent with valbenazine’s known profile. Conclusions Substantial improvements in QoL and TD severity were observed after 24 weeks of once-daily valbenazine, even in study participants with milder TD movements at baseline."

Clinical • HEOR • CNS Disorders • Mental Retardation • Mood Disorders • Movement Disorders • Schizophrenia

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Neurocrine Biosciences | Trial primary completion date: Apr 2027 ➔ Jan 2027 | Trial completion date: Apr 2027 ➔ Jan 2027

Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Virginia Commonwealth University | Trial completion date: Jan 2026 ➔ Apr 2026 | Trial primary completion date: Jan 2026 ➔ Apr 2026

Trial completion date • Trial primary completion date • CNS Disorders • Dystonia • Movement Disorders

Additional presentations at the 2026 American College of Neuropsychopharmacology Annual Meeting (PRNewswire)

P3 data • CNS Disorders • Huntington's Disease

Net Product Sales Highlights (PRNewswire) - "INGREZZA fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion, reflecting 7% and 9% growth year-over-year, respectively. Results reflected double-digit prescription volume growth in TRx and NRx driven by strong patient demand, partially offset by a lower net price due to new formulary access investments to support long-term growth."

Sales • CNS Disorders • Genetic Disorders • Huntington's Disease